Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Jazz Pharmaceuticals Raises FY2025 Adj EPS Guidance from $4.80-$5.60 to $7.65-$8.45 vs $5.33 Est; Narrows FY2025 Sales Guidance from $4.150B-$4.300B to $4.175B-$4.275B vs $4.221B Est

Author: Benzinga Newsdesk | November 05, 2025 04:18pm
Jazz Pharmaceuticals (NASDAQ:JAZZ) raises FY2025 Adj EPS guidance from $4.80-$5.60 to $7.65-$8.45 vs $5.33 analyst estimate. Narrows FY2025 sales outlook from $4.150 billion-$4.300 billion to $4.175 billion-$4.275 billion vs $4.221 billion estimate.

Posted In: JAZZ


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist